Fresenius 

€43.04
957
+€0.89+2.11% 10:42 Today

Statistics

Day High
43.16
Day Low
42.12
52W High
43.16
52W Low
42.12
Volume
1,170
Avg. Volume
-
Mkt Cap
24.24B
P/E Ratio
-
Dividend Yield
2.46%
Dividend
1.06

Upcoming

Dividends

2.46%Dividend Yield
May 26
€1.05
May 25
€1.00
May 23
€0.92
Jun 22
€0.26
Jun 22
€0.92
10Y Growth
6.68%
5Y Growth
3.6%
3Y Growth
4.5%
1Y Growth
5%

Earnings

5AugExpected
Q1 2026
Next
0.81
0.83
0.85
0.87
Expected EPS
0.8714037744508881
Actual EPS
N/A

Financials

5.53%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
22.87BRevenue
1.26BNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow FRE.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
DaVita
DVA
Mkt Cap15.08B
DaVita Inc. provides kidney dialysis services, directly competing with Fresenius's dialysis services.
Baxter International
BAX
Mkt Cap11.7B
Baxter International Inc. offers dialysis products and services, competing in the same healthcare segment as Fresenius.
Medtronic
MDT
Mkt Cap106.49B
Medtronic plc manufactures and sells device-based medical therapies, including those that compete with Fresenius's medical devices.
Boston Scientific
BSX
Mkt Cap67.09B
Boston Scientific Corporation develops, manufactures, and markets medical devices that are in direct competition with some of Fresenius's product offerings.
Johnson & Johnson
JNJ
Mkt Cap633.19B
Johnson & Johnson operates in the healthcare sector, offering products and services that compete across several of Fresenius's business lines.
Abbott Laboratories
ABT
Mkt Cap166.17B
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products that compete with Fresenius.
Stryker
SYK
Mkt Cap125.18B
Stryker Corporation specializes in medical devices, competing with Fresenius in the medical equipment and services market.
Zimmer Biomet
ZBH
Mkt Cap18.01B
Zimmer Biomet Holdings, Inc. manufactures and markets orthopedic reconstructive products, competing with Fresenius's medical devices segment.
Becton Dickinson
BDX
Mkt Cap43.56B
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products, competing with Fresenius.

About

Fresenius SE & Co. KGaA is a diversified healthcare enterprise delivering a broad spectrum of products and services across multiple sectors, including dialysis, hospital operations, and outpatient medical treatment. Its operations are structured into four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Fresenius Medical Care specializes in supporting individuals suffering from chronic kidney disease, supplying essential products like dialyzers, hemodialysis equipment, and associated disposable items, alongside comprehensive dialysis services. Fresenius Kabi focuses on the therapeutic management and care of acutely and chronically ill patients. Its portfolio encompasses a wide range of offerings, including intravenous generic pharmaceuticals for areas like oncology, pain management, anesthesia, infection control, and critical care. It also provides parenteral and enteral nutritional solutions, infusion fluids, blood volume expanders, and biosimilar drugs targeting autoimmune and oncological conditions. Furthermore, the segment supplies medical devices and consumables vital for administering IV medications, infusion therapies, and clinical nutrition, along with transfusion products for blood component collection and various bodily treatments. Fresenius Helios manages a substantial network of healthcare facilities. In Germany, it operates 90 hospitals, around 130 outpatient clinics, and six prevention centers. Its Spanish presence includes 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers. Additionally, this segment extends its services to fertility treatment, operating 33 dedicated clinics and 39 supplementary locations spanning ten countries across three continents. Fresenius Vamed is dedicated to project management and service provision for hospitals and other healthcare infrastructure. Its comprehensive offerings range from project conception, detailed planning, and complete turnkey construction to ongoing maintenance, technical oversight, and operational administration. Originally established in 1912, the company was previously known as Fresenius SE before adopting its current name, Fresenius SE & Co. KGaA, in January 2011. Its global headquarters are situated in Bad Homburg vor der Höhe, Germany.
Show more...
CEO
Country
Germany
ISIN
DE0005785604

Listings

0 Comments

Share your thoughts

FAQ

What is Fresenius stock price today?
The current price of FRE.STU is €43.04 EUR — it has increased by +2.11% in the past 24 hours. Watch Fresenius stock price performance more closely on the chart.
What is Fresenius stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Fresenius stocks are traded under the ticker FRE.STU.
What is Fresenius market cap?
Today Fresenius has the market capitalization of 24.24B
When is the next Fresenius earnings date?
Fresenius is going to release the next earnings report on August 05, 2026.
What were Fresenius earnings last quarter?
FRE.STU earnings for the last quarter are 0.81 EUR per share, whereas the estimation was 0.86 EUR resulting in a -6.29% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Fresenius revenue for the last year?
Fresenius revenue for the last year amounts to 22.87B EUR.
What is Fresenius net income for the last year?
FRE.STU net income for the last year is 1.26B EUR.
Does Fresenius pay dividends?
Yes, FRE.STU dividends are paid annual. The last dividend per share was 1.05 EUR. As of today, Dividend Yield (FWD)% is 2.46%.
In which sector is Fresenius located?
Fresenius operates in the Materials sector.
When did Fresenius complete a stock split?
The last stock split for Fresenius was on August 05, 2014 with a ratio of 1.5:1.